Development and validation of a prognostic 40-day mortality risk model among hospitalized patients with COVID-19
Donald A. Berry(Berry & Associates (United States)), Stuart L. Goldberg(Center for Discovery), Puneet Kaur(Vaal University of Technology), Rashmi Unawane(Hackensack University Medical Center), Katerina Trpeski(Hackensack University Medical Center), Scott Berry(Queen's University), Andrew McConnell(Hackensack University Medical Center), Andrew Ip(Hackensack University Medical Center), Zachary Sica(Hackensack University Medical Center), Andrew L. Pecora(Hackensack University Medical Center), Michael Koropsak(Hackensack University Medical Center), Kristen Wright(Hackensack University Medical Center), Mary Mrkulic(Hackensack University Medical Center), Burcu Sat(Hackensack University Medical Center), Michael Marafelias(Hackensack University Medical Center), Nicholas Berry(Berry & Associates (United States)), Urszula Bednarz(Hackensack University Medical Center), André Goy(Hackensack University Medical Center), Brett E. Lewis(Hackensack University Medical Center), Virginia Gadalla(Hackensack University Medical Center), Michelle Serna(Hackensack University Medical Center), Ihor S. Sawczuk
Cited by 9
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
|Journal of Clinical Oncology|2002|1.2k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980